GNLX

Genelux Corporation
CAPPED RATING

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Genelux Corporation (GNLX) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F). The rating has held at D+ for 7 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
C-
Factor Score 1.9 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.5
EV / EBITDA -1.9
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -28.5%
Price Return 12M -68.1%
Catalyst Signal 0.00
Market Cap $85.1M
TTM Revenue $8.0K
Price / Sales 10.6K
ROE -177.9%

Historical Factor Score Progression

Held D+ for 7 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 F (0.0) C- (1.9) D+ (1.8) C- (2.0) C+ (2.6) D+ (1.7)
2026-11-05 F (0.0) C- (1.9) D+ (1.8) C- (2.1) C+ (2.7) D+ (1.7)
2026-10-29 F (0.0) C- (1.9) C- (1.9) C- (2.0) C+ (2.7) D+ (1.7)
2026-10-22 F (0.0) C- (1.9) D+ (1.8) C- (1.9) C+ (2.6) D+ (1.7)
2026-10-15 F (0.0) C- (1.9) D+ (1.8) C- (2.1) C+ (2.6) D+ (1.7)
Page 1 of 4